Wednesday, June 10th, 2009
Recently, FDA issued a draft guidance titled Presenting Risk Information in Prescription Drug and Medical Device Promotion. The draft guidance outlines factors FDA considers when evaluating ads and labeling for prescription drugs, providing examples to illustrate the agency’s thinking. According to FDA, the guidance was issued in response to requests ...
Posted in
FDA Files, Sales & Marketing |
1 Comment »
|
|
